公开(公告)号：US20070298028A1

公开(公告)日：2007-12-27

申请号：US10589676

申请日：2005-02-04

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

IPC分类号： A61K39/395 ,  A61K31/7052 ,  A61K38/02 ,  A61P15/00 ,  A61P3/00 ,  A61P5/00 ,  C12Q1/68 ,  G01N33/68 ,  G01N33/53 ,  A61P9/00 ,  A61P35/00 ,  A61P25/00 ,  A61P13/00 ,  A61K38/16

CPC分类号： C12Q1/37 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57442 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2500/00 ,  Y10T436/143333

摘要： The invention provides a human KLK3 which is associated with the endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK3 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与内分泌系统和激素失调，心血管疾病，代谢疾病，癌症疾病，神经障碍，泌尿系统疾病和繁殖障碍有关的人类KLK3。 本发明还提供了用于鉴定可用于治疗或预防内分泌系统和激素障碍，心血管疾病，代谢疾病，癌症疾病，神经障碍，泌尿系统疾病和繁殖障碍的化合物的测定。 本发明还涉及结合和/或活化或抑制KLK3活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070280886A1

公开(公告)日：2007-12-06

申请号：US11659742

申请日：2005-08-31

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： A61K31/7052 ,  A61K38/17 ,  A61P1/00 ,  A61P11/00 ,  A61P13/00 ,  A61P17/00 ,  A61P19/00 ,  A61P25/00 ,  A61P3/00 ,  A61P35/00 ,  A61P5/00 ,  A61P7/00 ,  A61P9/00 ,  G01N33/53 ,  G01N33/68

CPC分类号： C12Q1/6883 ,  C07K14/72 ,  C12Q2600/158 ,  G01N33/74 ,  G01N2333/726 ,  G01N2500/04

摘要： The invention provides a human AMDR which is associated with the cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenteroloigcal diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AMDR as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与心血管疾病，感染，皮肤病，内分泌疾病，代谢疾病，胃肠疾病，癌症，炎症，血液疾病，呼吸系统疾病，肌肉骨骼疾病，神经系统疾病，泌尿科疾病有关的人类AMDR。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，感染，皮肤病，内分泌疾病，代谢疾病，胃肠神经病，癌症，炎症，血液疾病，呼吸系统疾病，肌肉骨骼疾病，神经系统疾病 ，泌尿系疾病。 本发明还涉及结合和/或活化或抑制AMDR活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070269421A1

公开(公告)日：2007-11-22

申请号：US10588067

申请日：2005-01-22

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

IPC分类号： A61K31/7088 ,  A61K38/16 ,  A61K39/395 ,  A61P29/00 ,  A61P3/00 ,  A61P35/00 ,  A61P9/00 ,  C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/6896 ,  C12Q1/37 ,  G01N33/573 ,  G01N33/6893

摘要： The invention provides a human PGCP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PGCP as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与心血管疾病，内分泌疾病，代谢疾病，癌症，炎症，胃肠疾病，血液疾病，呼吸系统疾病，肌肉骨骼疾病，神经系统疾病和泌尿系疾病有关的人类PGCP。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，内分泌疾病，代谢疾病，癌症，炎症，胃肠疾病，血液疾病，呼吸系统疾病，肌肉骨骼疾病，神经疾病和泌尿系疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制PGCP活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070202500A1

公开(公告)日：2007-08-30

申请号：US10573582

申请日：2004-09-16

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/10

CPC分类号： C12N9/1029

摘要： The present invention is directed to a polynucleotide and polypeptide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X2. The invention also provides the human MGAT-X2 associated with the cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases. The invention also provides assays for the identification of compounds useful for the modulation of cardiovascular diseases, dermatological diseases, metabolic diseases or muscle-skeleton disorders for treating of cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases associated with expression of the MGAT-X2. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X2 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明涉及新型酰基甘油酰基转移酶样蛋白MGAT-X2的多核苷酸和多肽序列。 本发明还提供了与心血管疾病，代谢疾病，肌肉骨骼疾病或皮肤病学疾病相关的人MGAT-X2。 本发明还提供了用于鉴定可用于调节心血管疾病，皮肤病学疾病，代谢疾病或用于治疗心血管疾病的肌肉骨骼疾病，代谢疾病，肌肉骨骼疾病或与MGAT表达相关的皮肤病学疾病的化合物的测定 -X2。 本发明还涉及结合和/或活化或抑制MGAT-X2的活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070148175A1

公开(公告)日：2007-06-28

申请号：US10586529

申请日：2005-01-15

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts ,  Holger Summer

IPC分类号： A61K48/00 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/395 ,  A61K38/55

CPC分类号： C12N9/6445

摘要： The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK12 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与胃肠和肝脏疾病，癌症疾病，血液疾病，炎性疾病，呼吸系统疾病，神经障碍，心血管疾病，繁殖障碍和泌尿系统疾病相关的人类KLK12。 本发明还提供了用于鉴定可用于治疗或预防胃肠和肝脏疾病，癌症疾病，血液疾病，炎性疾病，呼吸系统疾病，神经障碍，心血管疾病，繁殖障碍和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制KLK12活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070128603A1

公开(公告)日：2007-06-07

申请号：US10558297

申请日：2004-05-15

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G01N33/942 ,  C07K14/70571 ,  G01N2333/4719 ,  G01N2500/20

摘要： The invention provides a human 5-HT7 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT7 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供与心血管疾病，皮肤病，胃肠和肝脏疾病，癌症疾病，炎性疾病，代谢疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病有关的人类5-HT7。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，皮肤病，胃肠和肝脏疾病，癌症疾病，炎性疾病，代谢疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制5-HT7活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20070065801A1

公开(公告)日：2007-03-22

申请号：US10557887

申请日：2004-05-12

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： C12Q1/00 ,  C12Q1/68 ,  G01N33/567

CPC分类号： C07K14/70571 ,  G01N33/9406 ,  G01N33/942 ,  G01N2500/00

摘要： The invention provides a human 5-HT4 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT4 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供与心血管疾病，胃肠和肝脏疾病，炎性疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病有关的人类5-HT4。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，胃肠和肝脏疾病，炎性疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制5-HT4活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20060281085A1

公开(公告)日：2006-12-14

申请号：US10548404

申请日：2004-02-27

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： C12Q1/68 ,  C12Q1/42

CPC分类号： G01N33/6893 ,  C12Q1/44 ,  G01N33/57484

摘要： The invention provides a human PDE1B which is associated with the cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1B as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与心血管疾病，代谢疾病，胃肠和肝脏疾病，癌症疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病相关的人PDE1B。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，代谢疾病，胃肠和肝脏疾病，癌症疾病，血液病症，呼吸系统疾病，神经障碍和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制PDE1B活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20060188882A1

公开(公告)日：2006-08-24

申请号：US10548423

申请日：2004-02-27

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Andreas Geerts

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07K14/82

CPC分类号： C12Q1/44 ,  G01N33/57484 ,  G01N33/6893

摘要： The invention provides a human PDE1C which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1C as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供与心血管疾病，胃肠和肝脏疾病，癌症疾病，神经障碍，呼吸系统疾病和泌尿系统疾病相关的人PDE1C。 本发明还提供了用于鉴定可用于治疗或预防心血管疾病，胃肠和肝脏疾病，癌症疾病，神经障碍，呼吸系统疾病和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制PDE1C活性的化合物以及包含这些化合物的药物组合物。

公开(公告)号：US20060160088A1

公开(公告)日：2006-07-20

申请号：US10544614

申请日：2004-02-04

申请人： Stefan Golz ,  Ulf Bruggemeier ,  Holger Summer

发明人： Stefan Golz ,  Ulf Bruggemeier ,  Holger Summer

IPC分类号： C12Q1/68 ,  G01N33/567 ,  A61K39/395 ,  A61K48/00 ,  A61K38/17

CPC分类号： G01N33/92

摘要： The invention provides a human GPR40 which is associated with the hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR40 as well as pharmaceutical compositions comprising such compounds.

摘要翻译： 本发明提供了与血液疾病，外周和中枢神经系统疾病，胃肠疾病，呼吸系统疾病，代谢疾病，癌症，心血管疾病和泌尿系疾病有关的人GPR40。 本发明还提供了用于鉴定可用于治疗或预防血液疾病，外周和中枢神经系统疾病，胃肠道疾病，呼吸系统疾病，代谢疾病，癌症，心血管疾病和泌尿系统疾病的化合物的测定。 本发明还涉及结合和/或活化或抑制GPR40活性的化合物以及包含这些化合物的药物组合物。